SomaLogic, Inc. provided revenue guidance for the year 2022. Based on ongoing strength in its business, the company is maintaining revenue guidance for the full year 2022 at a range of $105 million to $110 million, which represents 29% to 35% growth over the company's 2021 revenue.
Standard BioTools Inc.
Equities
SLGC
US83444K1051
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+40.80% | 55.66B | |
-8.05% | 38.98B | |
+35.79% | 38.8B | |
-8.98% | 27.32B | |
+10.69% | 26.29B | |
-16.21% | 20.25B | |
+31.00% | 12.76B | |
+28.51% | 12.18B | |
-1.67% | 12.12B |